Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options... Show more
ATNM's Aroon Indicator triggered a bullish signal on April 04, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 102 similar instances where the Aroon Indicator showed a similar pattern. In of the 102 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 73 cases where ATNM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on April 22, 2025. You may want to consider a long position or call options on ATNM as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
ATNM moved above its 50-day moving average on April 25, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for ATNM moved out of overbought territory on March 31, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for ATNM turned negative on April 03, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
The 10-day moving average for ATNM crossed bearishly below the 50-day moving average on April 16, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ATNM broke above its upper Bollinger Band on March 26, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.362) is normal, around the industry mean (14.342). P/E Ratio (0.000) is within average values for comparable stocks, (64.236). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.830). Dividend Yield (0.000) settles around the average of (0.023) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (254.940).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology
A.I.dvisor indicates that over the last year, ATNM has been loosely correlated with GBIO. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNM jumps, then GBIO could also see price increases.
Ticker / NAME | Correlation To ATNM | 1D Price Change % | ||
---|---|---|---|---|
ATNM | 100% | +10.00% | ||
GBIO - ATNM | 46% Loosely correlated | -2.09% | ||
AURA - ATNM | 35% Loosely correlated | +0.91% | ||
IMNM - ATNM | 34% Loosely correlated | -0.47% | ||
ABCL - ATNM | 34% Loosely correlated | -1.54% | ||
PRLD - ATNM | 34% Loosely correlated | +1.61% | ||
More |